Invention Grant
- Patent Title: Selective NR2B antagonists
-
Application No.: US16502684Application Date: 2019-07-03
-
Publication No.: US10961229B2Publication Date: 2021-03-30
- Inventor: Imadul Islam , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Srinivas Cheruku , Poornima Shetty , Grandhi Venkat Ram Krishna Mohan Gupta , John E. Macor
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Priority: IN3308/DEL/15 20151014
- Main IPC: C07D403/14
- IPC: C07D403/14 ; C07D401/12 ; C07D471/08 ; A61P25/28 ; A61P25/02 ; A61P25/24 ; A61P25/16 ; C07D401/14 ; C07D487/08
Abstract:
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Public/Granted literature
- US20200071304A1 SELECTIVE NR2B ANTAGONISTS Public/Granted day:2020-03-05
Information query
